Heart failure (HF) is a complex clinical syndrome characterized by the activation of at least
several neurohumoral pathways that have a common role in maintaining cardiac output and …

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure with preserved ejection fraction, but additional data …

There is a lack of consensus on how we define heart failure with preserved ejection fraction
(HFpEF), with wide variation in diagnostic criteria across society guidelines. This lack of …

Importance Adding a sodium-glucose cotransporter-2 inhibitor (SGLT2-I) to standard-of-care
treatment in patients with heart failure with preserved ejection fraction (HFpEF) reduces the …

Importance The Centers for Medicare & Medicaid Services and the Veterans Affairs Health
Care System provide incentives for hospitals to reduce 30-day readmission and mortality …

Heart failure with preserved ejection fraction (HFpEF) is highly prevalent and is associated
with relevant morbidity and mortality. However, an evidence-based treatment is still absent …

Heart failure with preserved ejection fraction (HFpEF) is problematic to treat, with guidelines
for HFpEF management concentrated on treating prevalent comorbidities. The aim of this …

Background Hospitalization for heart failure (HHF) is associated with poor postdischarge
outcomes but the role of time since most recent HHF and potential treatment interactions are …

Given the role of comorbid conditions in the pathophysiology of HFpEF, we aimed to identify
and rank the importance of comorbid conditions associated with post-hospitalization …

Background/Purpose Thirty-day hospital readmission rate significantly raised with advanced
age. The performance of existing predictive models for readmission risk remained uncertain …